Noboru Nakaigawa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5854897/publications.pdf

Version: 2024-02-01

36	1,548	430874	330143
papers	citations	18 h-index	37 g-index

43	43	43	1921
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Roughness of the renal tumor surface could predict the surgical difficulty of robotâ€assisted partial nephrectomy. Asian Journal of Endoscopic Surgery, 2022, 15, 591-598.	0.9	2
2	Correlation of urinary loss rate after catheter removal and longâ€term urinary continence after robotâ€assisted laparoscopic radical prostatectomy. International Journal of Urology, 2021, 28, 440-443.	1.0	6
3	Urological Cancer. , 2021, , 77-93.		0
4	Development of a Microfluidic Device to Form a Long Chemical Gradient in a Tissue from Both Ends with an Analysis of Its Appearance and Content. Micromachines, 2021, 12, 1482.	2.9	3
5	A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma. Anticancer Research, 2021, 41, 6199-6209.	1.1	7
6	Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis. World Journal of Urology, 2020, 38, 2477-2484.	2.2	16
7	C-reactive protein at 1Âmonth after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2020, 86, 75-85.	2.3	10
8	A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 5089-5089.	1.6	5
9	Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. BMC Cancer, 2019, 19, 298.	2.6	24
10	The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer. BioMed Research International, 2019, 2019, 1-5.	1.9	4
11	FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 739-744.	2.3	15
12	Time-dependent change in relapse sites of renal cell carcinoma after curative surgery. Clinical and Experimental Metastasis, 2018, 35, 69-75.	3.3	15
13	PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. BMC Urology, 2018, 18, 97.	1.4	36
14	BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. Human Molecular Genetics, 2018, 27, 2712-2724.	2.9	14
15	Histopathological analysis of aggressive renal cell carcinoma harboring a unique germline mutation in fumarate hydratase. Pathology International, 2018, 68, 473-478.	1.3	4
16	Renal Cell Carcinoma in a Horseshoe Kidney Treated with Laparoscopic Partial Nephrectomy. Case Reports in Oncological Medicine, 2018, 2018, 1-3.	0.3	11
17	One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival. Cancer Chemotherapy and Pharmacology, 2017, 79, 855-861.	2.3	16
18	The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy. BMC Cancer, 2017, 17, 39.	2.6	24

#	Article	IF	Citations
19	Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma. Case Reports in Oncological Medicine, 2017, 2017, 1-3.	0.3	2
20	A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International, 2017, 2017, 1-4.	1.9	25
21	A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy. BMC Urology, 2017, 17, 87.	1.4	40
22	Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International, 2016, 2016, 1-5.	1.9	11
23	Essential content of evidenceâ€based clinical practice guidelines for bladder cancer: The Japanese Urological Association 2015 update. International Journal of Urology, 2016, 23, 640-645.	1.0	30
24	FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. BMC Cancer, 2016, 16, 67.	2.6	54
25	Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy. BMC Cancer, 2016, 16, 185.	2.6	46
26	Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget, 2015, 6, 32169-32176.	1.8	53
27	The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. BMC Cancer, 2014, 14, 390.	2.6	26
28	Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer, 2012, 12, 162.	2.6	68
29	C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy. BMC Cancer, 2012, 12, 337.	2.6	20
30	Evaluation of Response to Multikinase Inhibitor in Metastatic Renal Cell Carcinoma by FDG PET/Contrast-Enhanced CT. Clinical Nuclear Medicine, 2010, 35, 918-923.	1.3	30
31	Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer, 2010, 10, 667.	2.6	89
32	Improvement on parenchymal suturing technique in laparoscopic partial nephrectomy. International Journal of Urology, 2008, 15, 854-855.	1.0	10
33	Inactivation of von Hippel-Lindau Gene Induces Constitutive Phosphorylation of MET Protein in Clear Cell Renal Carcinoma. Cancer Research, 2006, 66, 3699-3705.	0.9	89
34	Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor. Oncogene, 2003, 22, 2728-2738.	5.9	97
35	Oncogenic Mutants of RON and MET Receptor Tyrosine Kinases Cause Activation of the Î²-Catenin Pathway. Molecular and Cellular Biology, 2001, 21, 5857-5868.	2.3	155
36	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 1999, 18, 2343-2350.	5.9	487